25-Hydroxyvitamin D-1α-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer

Journal of Steroid Biochemistry and Molecular Biology

Volumn 81, Issue 2, 2002, Pages 135-140

  Whitlatch, Lyman W ^a,b   Young, Michael V ^a   Schwartz, Gary G ^c   Flanagan, John N ^a,b   Burnstein, Kerry L ^d   Lokeshwar, Bal L ^d   Rich, Edwin S ^a   Holick, Michael F ^a,b   Chen, Tai C ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Cell culture; Cytochrome P 450; LNCaP; Vitamin D

Indexed keywords

CALCIDIOL 1 MONOOXYGENASE; CALCITRIOL;

ARTICLE; CANCER CELL; CONTROLLED STUDY; DNA TRANSFECTION; ENZYME ACTIVITY; GENE THERAPY; GENE TRANSFER; HUMAN; HUMAN CELL; MALE; PROSTATE CANCER; PROSTATE HYPERTROPHY;

NON-PROGRAMMATIC;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; CELLS, CULTURED; HUMANS; MALE; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0036345365     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(02)00053-5     Document Type: Article

References (27)

1. Is Vitamin D deficiency a risk factor for prostate cancer? (Hypothesis)
2. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland)
3. Vitamin D: Photobiology, metabolism, and clinical applications
4. Current understanding of the molecular actions of Vitamin D
5. 3
6. 3 on primary cultures of human prostatic cells
7. Human prostate cancer cells: Inhibition of proliferation by Vitamin D analogs
8. 2 for prostate cancer therapy
9. 3
10. 3
11. Vitamin D and prostate cancer
12. 3
13. Secretion of matrix metalloproteinases and their inhibitors (TIMPs) by human prostate in explant cultures: Reduced tissue inhibitor of metalloproteinase secretion by malignant tissues
14. Enhancing 1α-hydroxylase activity with the 25-hydroxyvitamin D-1α-hydroxylase gene in cultured human keratinocytes and mouse skin
15. 3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation
16. 3 by solubilized kidney mitochondria from chick and rat
17. 3 are potentiated by epidermal growth factor and attenuated by insulin in cultured human keratinocytes
18. Metabolism and catabolism of Vitamin D, its metabolites, and clinically relevant analogs
19. 3-induced growth inhibition
20. 3-1α-hydroxylase in cultured human prostatic cells
21. Extrarenal production of calcitriol
22. Vitamin D receptor polymorphisms, circulating Vitamin D metabolites, and risk of prostate cancer in United States physicians
23. Gene therapy for prostate cancer
24. The current status of gene therapy for prostate cancer
25. Phase II trial of oral 1α,25-dihydroxyyitamin D (calcitriol) in hormone refractory prostate cancer
26. 3 (calcitriol)